IBRX R&D to Revenue
Immunitybio Inc · R&D to Revenue
IBRX R&D to Revenue
Latest reported112.59%period ending
IBRX Quarterly R&D/Revenue (0.00% → 112.59%)
Latest values, visible window
High-resolution chart · PNG
IBRX r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 112.5878% | |
| 146.5186% | |
| 158.8298% | |
| 158.2359% | |
| 209.0293% | |
| 292.0264% | |
| 466.3798% | |
| 826.1218% | |
| 4,883.3811% | |
| 133,377.5% | |
| 37,073.3813% | |
| 59,026.8293% | |
| 129,678.0488% | |
| 21,878.8889% | |
| 72,398.6301% | |
| 56,874.5763% | |
| 167,537.1429% | |
| 366,342.8571% | |
| 13,270% | |
| 74,662.1212% | |
| 15,870.2065% | |
| 29,588.4892% | |
| 96,457.1429% | |
| 23,690.0662% | |
| 7,569.9541% | |
| 16,590.303% | |
| 1,434.0217% | |
| 100,433.3333% | |
| 77,241.1765% | |
| 251,960% | |
| 178,285.7143% | |
| 46,964.5161% | |
| 367,200% | |
| 279,820% | |
| 100,175% | |
| 138,362.5% | |
| 69,328.5714% | |
| 84,072.7273% | |
| 67,464.2857% | |
| 69,700% | |
| 53,241.6667% | |
| 82,400% | |
| 36,471.4286% | |
| 39,500% | |
| 1,917.5824% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |